Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Myeloid 1Lymphoid 1Head & Neck 1Genitourinary 1CNS 1Breast 1

Conditions

Breast Neoplasms 369Carcinoma, Non-Small-Cell Lung 315Neoplasms 289Prostatic Neoplasms 245Colorectal Neoplasms 214Multiple Myeloma 182Lung Neoplasms 170Neoplasm Metastasis 152Leukemia, Myeloid, Acute 137Pancreatic Neoplasms 130Squamous Cell Carcinoma of Head and Neck 127Ovarian Neoplasms 117Melanoma 98Carcinoma, Renal Cell 94Recurrence 87Stomach Neoplasms 81Precursor Cell Lymphoblastic Leukemia-Lymphoma 80Carcinoma, Hepatocellular 80Lymphoma, Non-Hodgkin 79Head and Neck Neoplasms 79Lymphoma 78Glioblastoma 78Triple Negative Breast Neoplasms 76Lymphoma, Large B-Cell, Diffuse 75Urinary Bladder Neoplasms 69Endometrial Neoplasms 68Brain Neoplasms 68Leukemia, Lymphocytic, Chronic, B-Cell 65Uterine Cervical Neoplasms 62Lymphoma, Follicular 62

Interventions

temsirolimus 1Valproic Acid 1Sirolimus 1Immunoglobulin G 1Disulfides 1Cetuximab 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Neoplasms, Mesothelial × 30 days × Clear all
NCT01552434 2026-05-15

Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease

M.D. Anderson Cancer Center

Phase 1 Terminated
154 enrolled
BreastCNSGenitourinaryHead & NeckLymphoidMyeloidSarcoma

Breast Neoplasms, Carcinoma, Transitional Cell, Endocrine Gland Neoplasms, Castleman Disease, Mouth Neoplasms, Neoplasm Metastasis, Neoplasms, Pharyngeal Neoplasms, Recurrence, Sarcoma, Soft Tissue Neoplasms, Thyroid Neoplasms, Urologic Neoplasms, Neurofibromatosis 2, Lymphangioleiomyomatosis, Neoplasms, Mesothelial, Erdheim-Chester Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡